JP2024524613A - M6pr細胞表面受容体結合化合物及びコンジュゲート - Google Patents

M6pr細胞表面受容体結合化合物及びコンジュゲート Download PDF

Info

Publication number
JP2024524613A
JP2024524613A JP2024501118A JP2024501118A JP2024524613A JP 2024524613 A JP2024524613 A JP 2024524613A JP 2024501118 A JP2024501118 A JP 2024501118A JP 2024501118 A JP2024501118 A JP 2024501118A JP 2024524613 A JP2024524613 A JP 2024524613A
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
conjugate
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524613A5 (cg-RX-API-DMAC7.html
Inventor
ブレット ブラッドリー ブッシュ,
ジャスティン トーマス アーンスト,
ギャリック ケー. パッカード,
ジェイソン ジー. ルイス,
エリック ディー. タートル,
Original Assignee
ライシア セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライシア セラピューティクス, インコーポレイテッド filed Critical ライシア セラピューティクス, インコーポレイテッド
Publication of JP2024524613A publication Critical patent/JP2024524613A/ja
Publication of JP2024524613A5 publication Critical patent/JP2024524613A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024501118A 2021-07-14 2022-07-14 M6pr細胞表面受容体結合化合物及びコンジュゲート Pending JP2024524613A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221915P 2021-07-14 2021-07-14
US63/221,915 2021-07-14
PCT/US2022/037196 WO2023288015A1 (en) 2021-07-14 2022-07-14 M6pr cell surface receptor binding compounds and conjugates

Publications (2)

Publication Number Publication Date
JP2024524613A true JP2024524613A (ja) 2024-07-05
JP2024524613A5 JP2024524613A5 (cg-RX-API-DMAC7.html) 2025-07-23

Family

ID=82786881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501118A Pending JP2024524613A (ja) 2021-07-14 2022-07-14 M6pr細胞表面受容体結合化合物及びコンジュゲート

Country Status (7)

Country Link
US (1) US20240335544A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370156A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024524613A (cg-RX-API-DMAC7.html)
CN (1) CN117915956A (cg-RX-API-DMAC7.html)
AU (1) AU2022310346A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226268A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023288015A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
EP4651904A1 (en) 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Lysosomal targeting bifunctional molecules for degradation of autoantibodies
EP4651901A1 (en) 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Cycling lysosomal targeting antibody conjugates
WO2024155748A1 (en) * 2023-01-18 2024-07-25 Lycia Therapeutics, Inc. M6pr binding compounds and conjugates
WO2024182772A2 (en) * 2023-03-02 2024-09-06 Avilar Therapeutics, Inc. Mannose 6-phosphate receptor binding compounds for the degradation of extracellular proteins
FR3149188A1 (fr) * 2023-05-31 2024-12-06 Nanomedsyn Pro-ligands, conjugués comprenant lesdits pro-ligands et leurs utilisations pour des applications thérapeutiques
WO2025021155A1 (zh) * 2023-07-25 2025-01-30 深圳湾实验室 一种多特异性结合蛋白及其应用
WO2026015664A1 (en) 2024-07-10 2026-01-15 Lycia Therapeutics, Inc. Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104015A2 (en) * 2003-05-20 2004-12-02 Pharmaxis Pty Ltd. Mannose-6-phosphonate compounds for the treatment of inflammatory diseases
EP3301175A1 (en) * 2016-09-30 2018-04-04 Rijksuniversiteit Groningen Means and methods for mobilizing hematopoietic stem cells (hscs)
US20180265534A1 (en) * 2015-09-18 2018-09-20 Nanomedsyn Multi-functionalized polysaccharide compounds and use thereof for targeting the cation-independent mannose 6-phosphate receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
BR112018069147A2 (pt) * 2016-03-23 2019-01-22 Fimbrion Therapeutics Inc composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh
EP3897747A4 (en) 2018-12-19 2022-12-07 The Board of Trustees of the Leland Stanford Junior University BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS
US20230051872A1 (en) 2019-03-22 2023-02-16 Reflexion Pharmaceuticals, Inc. Multivalent D-Peptidic Compounds for Target Proteins
EP3941580A1 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
EP4087584A4 (en) * 2020-01-10 2024-08-28 Lycia Therapeutics, Inc. Cell surface receptor binding compounds and conjugates
US20230226214A1 (en) * 2020-06-24 2023-07-20 Lycia Therapeutics, Inc. Bifunctional bridging compositions for viral transduction
EP4171658A4 (en) * 2020-06-24 2025-04-09 Lycia Therapeutics, Inc. Modified viral compositions for viral transduction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104015A2 (en) * 2003-05-20 2004-12-02 Pharmaxis Pty Ltd. Mannose-6-phosphonate compounds for the treatment of inflammatory diseases
US20180265534A1 (en) * 2015-09-18 2018-09-20 Nanomedsyn Multi-functionalized polysaccharide compounds and use thereof for targeting the cation-independent mannose 6-phosphate receptor
EP3301175A1 (en) * 2016-09-30 2018-04-04 Rijksuniversiteit Groningen Means and methods for mobilizing hematopoietic stem cells (hscs)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"RN:732237-41-1", REGISTRY(STN), JPN7026002560, 25 August 2004 (2004-08-25), ISSN: 0005882545 *
BARRAGAN V. ET AL., CHEM. COMMUN., JPN6025011179, 2001, pages 85 - 86, ISSN: 0005882544 *

Also Published As

Publication number Publication date
WO2023288015A1 (en) 2023-01-19
AU2022310346A1 (en) 2024-01-25
US20240335544A1 (en) 2024-10-10
EP4370156A1 (en) 2024-05-22
CN117915956A (zh) 2024-04-19
CA3226268A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
US12258332B2 (en) ASGPR cell surface receptor binding compounds and conjugates
US20240335544A1 (en) M6pr cell surface receptor binding compounds and conjugates
US20230158155A1 (en) Cell Surface Receptor Binding Compounds and Conjugates
KR102713173B1 (ko) 비스-옥타하이드로페난트렌 카복스아미드 및 이의 단백질 접합체
EP3908323A2 (en) Traceless linkers and protein-conjugates thereof
CN115651056A (zh) 类固醇类化合物及其蛋白质-偶联物
TW202241522A (zh) 免疫刺激化合物及結合物
CN113444111A (zh) 新型苯二氮杂䓬衍生物及其用途
JP2026503463A (ja) Asgpr結合化合物およびコンジュゲート
JP2026509055A (ja) M6pr結合化合物およびコンジュゲート
JP2026503461A (ja) サイクリングリソソーム標的化抗体コンジュゲート
EA047045B1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
EA046545B1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260610